Louise Chen
Stock Analyst at Scotiabank
(3.14)
# 1,225
Out of 4,981 analysts
300
Total ratings
46.34%
Success rate
0.7%
Average return
Main Sectors:
Stocks Rated by Louise Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Upgrades: Sector Outperform | $80 | $17.91 | +346.68% | 3 | Jun 6, 2025 | |
| ACRS Aclaris Therapeutics | Maintains: Sector Outperform | $15 → $9 | $1.97 | +356.85% | 6 | May 9, 2025 | |
| EWTX Edgewise Therapeutics | Downgrades: Sector Perform | $50 → $14 | $14.67 | -4.57% | 2 | Apr 3, 2025 | |
| GANX Gain Therapeutics | Initiates: Sector Outperform | $12 | $1.72 | +597.67% | 1 | Mar 7, 2025 | |
| INVA Innoviva | Initiates: Sector Outperform | $55 | $19.43 | +183.07% | 5 | Mar 7, 2025 | |
| PTCT PTC Therapeutics | Initiates: Sector Perform | $55 | $60.96 | -9.78% | 1 | Mar 7, 2025 | |
| CATX Perspective Therapeutics | Initiates: Sector Outperform | $15 | $3.38 | +343.79% | 1 | Mar 7, 2025 | |
| PVLA Palvella Therapeutics | Initiates: Sector Outperform | $50 | $58.45 | -14.46% | 1 | Mar 7, 2025 | |
| ARDX Ardelyx | Initiates: Sector Outperform | $15 | $6.68 | +124.55% | 5 | Mar 7, 2025 | |
| COGT Cogent Biosciences | Initiates: Sector Outperform | $17 | $12.81 | +32.71% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $70 | $41.04 | +70.57% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $50 | $13.18 | +279.51% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $30 | $10.15 | +195.57% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $55 | $32.48 | +69.33% | 8 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.95 | - | 5 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $160 | $54.30 | +194.66% | 20 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $33.06 | - | 6 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $200 → $240 | $220.22 | +8.98% | 6 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $45 | $24.86 | +81.01% | 31 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $215 | $178.50 | +20.45% | 40 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $7.95 | - | 5 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $155 | $85.15 | +82.03% | 25 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $14.41 | - | 9 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $885 | $756.28 | +17.02% | 45 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $7.51 | - | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $16.80 | - | 10 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $15.37 | - | 6 | Aug 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $6.33 | - | 3 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $64.87 | - | 6 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.82 | - | 3 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.75 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $14.87 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.18 | - | 2 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $925 | $568.20 | +62.79% | 1 | Apr 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.18 | - | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $65 | $3.28 | +1,881.71% | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $1.63 | +206.75% | 2 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $3.90 | +541.03% | 4 | Sep 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $16.40 | +204.88% | 3 | Sep 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $17.69 | +182.65% | 3 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $1.11 | +350.45% | 4 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $9 | $0.32 | +2,750.81% | 1 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $1,687,500 | $2.03 | +83,127,978.82% | 1 | Jul 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $240 → $258 | $370.50 | -30.36% | 1 | Mar 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $15 | $19.89 | -24.59% | 3 | Feb 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $50 | $1.28 | +3,806.25% | 2 | Jul 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.43 | +1,298.60% | 2 | Aug 18, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $7.35 | +512.24% | 1 | Jun 22, 2017 |
Sarepta Therapeutics
Jun 6, 2025
Upgrades: Sector Outperform
Price Target: $80
Current: $17.91
Upside: +346.68%
Aclaris Therapeutics
May 9, 2025
Maintains: Sector Outperform
Price Target: $15 → $9
Current: $1.97
Upside: +356.85%
Edgewise Therapeutics
Apr 3, 2025
Downgrades: Sector Perform
Price Target: $50 → $14
Current: $14.67
Upside: -4.57%
Gain Therapeutics
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $12
Current: $1.72
Upside: +597.67%
Innoviva
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $55
Current: $19.43
Upside: +183.07%
PTC Therapeutics
Mar 7, 2025
Initiates: Sector Perform
Price Target: $55
Current: $60.96
Upside: -9.78%
Perspective Therapeutics
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $15
Current: $3.38
Upside: +343.79%
Palvella Therapeutics
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $50
Current: $58.45
Upside: -14.46%
Ardelyx
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $15
Current: $6.68
Upside: +124.55%
Cogent Biosciences
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $17
Current: $12.81
Upside: +32.71%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $70
Current: $41.04
Upside: +70.57%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $50
Current: $13.18
Upside: +279.51%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $30
Current: $10.15
Upside: +195.57%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $55
Current: $32.48
Upside: +69.33%
Nov 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.95
Upside: -
Nov 6, 2024
Reiterates: Overweight
Price Target: $160
Current: $54.30
Upside: +194.66%
Nov 6, 2024
Reiterates: Overweight
Price Target: n/a
Current: $33.06
Upside: -
Oct 31, 2024
Maintains: Overweight
Price Target: $200 → $240
Current: $220.22
Upside: +8.98%
Oct 25, 2024
Reiterates: Overweight
Price Target: $45
Current: $24.86
Upside: +81.01%
Oct 16, 2024
Reiterates: Overweight
Price Target: $215
Current: $178.50
Upside: +20.45%
Oct 11, 2024
Reiterates: Overweight
Price Target: n/a
Current: $7.95
Upside: -
Oct 3, 2024
Reiterates: Overweight
Price Target: $155
Current: $85.15
Upside: +82.03%
Sep 19, 2024
Reiterates: Overweight
Price Target: n/a
Current: $14.41
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $885
Current: $756.28
Upside: +17.02%
Sep 16, 2024
Reiterates: Overweight
Price Target: n/a
Current: $7.51
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $16.80
Upside: -
Aug 29, 2024
Reiterates: Overweight
Price Target: n/a
Current: $15.37
Upside: -
Aug 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $6.33
Upside: -
Aug 14, 2024
Reiterates: Overweight
Price Target: n/a
Current: $64.87
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.82
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.75
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $14.87
Upside: -
May 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.18
Upside: -
Apr 15, 2024
Reiterates: Neutral
Price Target: $925
Current: $568.20
Upside: +62.79%
Apr 1, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.18
Upside: -
Jan 31, 2024
Reiterates: Overweight
Price Target: $65
Current: $3.28
Upside: +1,881.71%
Sep 13, 2023
Reiterates: Overweight
Price Target: $5
Current: $1.63
Upside: +206.75%
Sep 5, 2023
Reiterates: Overweight
Price Target: $25
Current: $3.90
Upside: +541.03%
Sep 5, 2023
Reiterates: Overweight
Price Target: $50
Current: $16.40
Upside: +204.88%
Aug 22, 2023
Reiterates: Overweight
Price Target: $50
Current: $17.69
Upside: +182.65%
Aug 17, 2023
Reiterates: Neutral
Price Target: $5
Current: $1.11
Upside: +350.45%
May 12, 2023
Maintains: Overweight
Price Target: $5 → $9
Current: $0.32
Upside: +2,750.81%
Jul 7, 2021
Initiates: Overweight
Price Target: $1,687,500
Current: $2.03
Upside: +83,127,978.82%
Mar 27, 2020
Maintains: Neutral
Price Target: $240 → $258
Current: $370.50
Upside: -30.36%
Feb 12, 2020
Maintains: Neutral
Price Target: $9 → $15
Current: $19.89
Upside: -24.59%
Jul 19, 2018
Maintains: Overweight
Price Target: $40 → $50
Current: $1.28
Upside: +3,806.25%
Aug 18, 2017
Initiates: Overweight
Price Target: $20
Current: $1.43
Upside: +1,298.60%
Jun 22, 2017
Initiates: Overweight
Price Target: $45
Current: $7.35
Upside: +512.24%